AstraZeneca Company Research Report

Company Overview

• Name: AstraZeneca

• Mission: To transform the future of healthcare by unlocking the power of what science can do for people, society, and the planet.

• Founded: Founded in 1913

• Key People:

• Michel Demaré: Non-Executive Chair of the Board

• Pascal Soriot: Executive Director and Chief Executive Officer

• Aradhana Sarin: Executive Director and Chief Financial Officer

• Pam Cheng: Executive Vice President, Global Operations & IT and Chief Sustainability Officer

• Headquarters: No specific information on the exact location.

• Number of Employees: More than 83,000 people worldwide.

• Revenue: No specific information is available.

• Known For: AstraZeneca is known as a global, science-led, patient-focused pharmaceutical company dedicated to developing life-changing medicines across Oncology, BioPharmaceuticals, and Rare Disease therapy areas.

Products

Oncology

• Description: AstraZeneca is at the forefront of oncology, with a comprehensive pipeline of next-generation medicines targeting solid tumours and haematological cancers. The focus is on pioneering research across six scientific platforms such as tumour drivers, immuno-oncology, and DNA damage response.

BioPharmaceuticals

• Description: The company is engaged in delivering long-lasting effects for chronic diseases in Cardiovascular, Renal & Metabolism, and Respiratory & Immunology areas. AstraZeneca aims to intervene early to protect vital organs and achieve disease remission.

Rare Disease

• Description: Through the acquisition of Alexion, AstraZeneca aims to transform the lives of people affected by rare diseases by developing innovative medicines and supportive technologies.

Recent Developments

• Strategic R&D Developments:

• In 2024, Shanghai was named as AstraZeneca’s fifth global strategic R&D centre.

• Investment of $300 million in a state-of-the-art cell therapy facility in Rockville, MD, US.

• Product Approvals and Launches:

• Enhertu: Approved in China for HER2-mutant metastatic non-small cell lung cancer as the first HER2-directed therapy.

• Tagrisso: Approved in the US for unresectable, Stage III EGFR-mutated lung cancer.

• Strategic Acquisitions and Launches:

• In 2021, AstraZeneca acquired Alexion, enhancing its capability in immunology and rare diseases.

• Launched Evinova in 2023, a health-tech business aimed at accelerating innovation in life sciences.

• Collaborations and Partnerships:

• Lung Ambition Alliance: Collaborated with International entities to double the five-year survival rate for lung cancer globally by 2025.

• Healthy Heart Africa: Commitment to tackling hypertension in Africa, with extensive healthcare worker training and blood pressure screenings since 2014.

Additional Insights

• R&D Focus Areas:

• Oncology

• Cardiovascular, Renal & Metabolism

• Respiratory & Immunology

• Vaccines and Immune Therapies

• Neuroscience and Rare Diseases via Alexion.

• Sustainability Commitment:

• AstraZeneca integrates sustainable practices across operations, aligning with its science-based Ambition Zero Carbon programme aiming at a carbon-negative value chain by 2030.

• Recent Clinical Outcomes:

• Imfinzi and Imjudo demonstrated significant survival benefits in advanced liver cancer.

• Notable research at ATS 2024 in respiratory and immune-mediated diseases showcasing pipeline strength.

This detailed research report on AstraZeneca encapsulates the critical company insights, including its extensive commitment to innovation and healthcare transformation through scientific advancements across various therapeutic areas.